With one of the Pre-covid Chinese deals (AE-37 - one of the cancer paths, I believe), GNBT made arrangements for the Chinese entity to hold clinical trials in Europe, even though they would only have rights in China. I'm 99% sure Joe said at that time that the European data would wholly owned by GNBT and would be able to be put toward FDA approval... thus the arrangement to do the trials in Europe, not China.

Does anyone else remember that?

If that is the case, I would wonder if BK could work out similar trials in countries (AU/NZ?) that could benefit them and also our work toward our FDA approval... but I'm far from an expert here, obviously.

I suppose this is a Q for the call. It would be nice if we could get a pre-call summary of next steps/hurdles for this process before the call...